Belnacasan clinical trials
Also written VX-765.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How each study uses belnacasan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2004 (1)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Vertex Pharmaceuticals Incorporated (3) · MedStar Health (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses belnacasan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19CompletedPhase 2MedStar HealthNCT05164120Written as BelnacasanHow we know
- A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial EpilepsyTerminatedPhase 2Vertex Pharmaceuticals IncorporatedNCT01501383Written as VX-765 Part AHow we know
- Study of VX-765 in Subjects With Treatment-resistant Partial EpilepsyCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT01048255Written as VX-765How we know
- Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765CompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT00205465Written as VX-765How we know
Codes
What other systems call belnacasan · ClinicalTrials.gg INT005089
- MeSH (NLM) C520022belnacasanOne source NLM
- UNII (FDA) 00OLE78529BELNACASANConfirmed FDA, NLM, Wikidata
- Wikidata Q27075000belnacasanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171755BelnacasanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C520022 | belnacasan | One source NLM |
| UNII (FDA) | 00OLE78529 | BELNACASAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27075000 | belnacasan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171755 | Belnacasan | One source FDA |
Also registered as o-desethyl-belnacasan (UNII Q257O24H4J).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.